Posted by Michael Wonder on 22 Dec 2022
ICER releases draft evidence report on treatments for Alzheimer’s disease
22 December 2022 - Registration now open for 5 January “Early Insights” webinar.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of emerging treatments donanemab (Eli Lilly) and lecanemab (Eisai) for the treatment of Alzheimer’s disease.
